

Supplementary Online Content

Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial

eFigure 1. Masking of Trial Medication

eFigure 2. Number of Enrolments per Site

eFigure 3. Number of Enrolments per Month

eFigure 4. Distributions of the Primary Outcome in the Post Hoc Analyses of the Primary Outcome Assigning Patients Who Had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)

eTables 1a and 1b. Randomizations in Error and Wrongly Entered Stratification Variables

eTable 2. Trial Medication Administration and Protocol Violations

eTable 3. Results of the Analysis of the Primary Outcome in the Per Protocol Population

eTable 4. Best-Worst/Worst-Best Case Analyses of the Primary Outcome

eTable 5. Post Hoc Analyses of the Primary Outcome Assigning Patients Who had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)

eTable 6. Analyses of the Single Components of Composite Outcomes

eTable 7. Results of the Unadjusted Analyses of Secondary Outcomes

eTable 8. All Serious Adverse Reactions and Serious Adverse Events

eTable 9. Use of Extracorporeal Membrane Oxygenation within 28 Days of Randomization

eTable 10. Discharge Against Medical Advice within 28 Days of Randomization

22	Contents	
23	List of eFigures.....	3
24	List of eTables.....	4
25	eMethods.....	5
26	The COVID STEROID 2 Trial Group.....	5
27	Acknowledgements.....	11
28	Inclusion Criteria.....	12
29	Exclusion Criteria.....	13
30	Baseline Characteristics.....	14
31	Outcome definitions.....	17
32	Criteria for Discontinuation of Trial Medication and Withdrawal.....	20
33	Trial Populations.....	21
34	Handling of Missing Data.....	22
35	Abstract Written before Breaking the Randomization Code.....	24
36	eFigures.....	25
37	eTables.....	30
38	eReferences.....	40
39		

40 **List of eFigures**

41

42 eFigure 1. Masking of Trial Medication 25

43 eFigure 2. Number of Enrolments per Site 27

44 eFigure 3. Number of Enrolments per Month..... 28

45 eFigure 4. Distributions of the Primary Outcome in the Post Hoc Analyses of the Primary Outcome

46 Assigning Patients Who had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive

47 Without Life Support) 29

48 **List of eTables**

49

50 eTable 1a and 1b. Randomizations in Error and Wrongly Entered Stratification Variables..... 30

51 eTable 2. Trial Medication Administration and Protocol Violations 31

52 eTable 3. Results of the Analysis of the Primary Outcome in the Per Protocol Population* 32

53 eTable 4. Best-Worst/Worst-Best Case Analyses of the Primary Outcome..... 33

54 eTable 5. *Post Hoc* Analyses of the Primary Outcome Assigning Patients Who had Died at Day 28

55 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)..... 34

56 eTable 6. Analyses of the Single Components of Composite Outcomes 35

57 eTable 7. Results of the Unadjusted Analyses of Secondary Outcomes..... 36

58 eTable 8. All Serious Adverse Reactions and Serious Adverse Events* 37

59 eTable 9. Use of Extracorporeal Membrane Oxygenation within 28 Days of Randomization* 38

60 eTable 10. Discharge Against Medical Advice within 28 Days of Randomization* 39

61

62 **eMethods**

63

64 **The COVID STEROID 2 Trial Group**

65

66 **Management Committee**

67 Anders Perner (Sponsor and Chair of Management Committee), Marie Warrer Munch
68 (International Coordinating Investigator), Maj-Brit Nørregaard Kjær (International Project Manager),
69 Anders Granholm (National investigator - Denmark), Morten Hylander Møller (National investigator
70 - Denmark), Tine Sylvest Meyhoff (National investigator - Denmark), Gitte Kingo Vesterlund
71 (National Project Manager - Denmark), Marie Helleberg (National investigator - Denmark), Thomas
72 Benfield (National investigator - Denmark), Balasubramanian Venkatesh (Co-chair), Naomi
73 Hammond (Senior Research Fellow and Operations Lead - Australia), Sharon Micallef (Project
74 Manager - Australia), Vivekanand Jha (Co-chair), Bharath Kumar Tirupakuzhi Vijayaraghavan
75 (National Investigator - India), Sheila Nainan Myatra (National Coordinating Investigator - India),
76 Maria Cronhjort (National Investigator - Sweden), Rebecka Rubenson Wahlin (National
77 Coordinating Investigator - Sweden), Stephan Jakob (National Investigator - Switzerland), Luca
78 Cioccarri (National Coordinating Investigator - Switzerland), Christian Gluud (Trialist), and Theis
79 Lange (Statistician).

80

81 **Management Committee for the Indian Sites**

82 Balasubramanian Venkatesh (Co-chair), Vivekanand Jha (Co-chair), Sheila Nainan Myatra
83 (National Coordinating Investigator), Naomi Hammond (Senior Research Fellow and Operations
84 Lead – Australia), Abhinav Bassi (Project Manager - India), Sharon Micallef (Project Manager -
85 Australia), Anubhuti Jha (Site Coordinator – India), Mallikarjuna Kunigari (Program Manager –
86 India), Bharath Kumar Tirupakuzhi Vijayaraghavan (National Investigator), Oommen John (Senior
87 Research Fellow – India), Ashwani Kumar (Research Associate – Australia and India), Anders
88 Perner (Sponsor), Marie Warrer Munch (International Coordinating Investigator), Maj-Brit
89 Nørregaard Kjær (International Project Manager).

90

91

92

93 **Regional Coordinating Centre for India**

94 The George Institute for Global Health, Sydney, Australia: Naomi Hammond, Ashwani Kumar,
95 Sharon Micallef, Dorrilyn Rajbhandari, Balasubramanian Venkatesh

96

97 **Local Coordinating Centre for India**

98 The George Institute for Global Health, New Delhi, India: Sumaiya Arfin, Abhinav Bassi, Nikita
99 Bathla, Anubhuti Jha, Vivekanand Jha, Oommen John, Rajesh Joshi, Mallikarjuna Kunigari.

100

101 **Independent Data Monitoring and Safety Committee**

102 Christian Hassager (Clinician), Manu Shankar-Hari (Trialist), and Susanne Rosthøj (Statistician).

103

104 **Site investigators and research staff**

105 The primary investigator at each site is marked with *.

106

107 Denmark

108 Department of Intensive Care, Copenhagen University Hospital – Rigshospitalet: Marie Warrer
109 Munch*, Anders Perner, Maj-Brit Nørregaard Kjær, Morten Hylander Møller, Anders Granholm,
110 Gitte Kingo Vesterlund, Tine Sylvest Meyhoff, Lene Russell, Kis Rønn Uhre, Ann Louise Syrach
111 Lindgaard, Jette Degn, Mik Wetterslev, Praleene Sivapalan, Carl Thomas Anthon, Vibe Sommer
112 Mikkelsen, Louise Colette la Porte, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno
113 Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan
114 Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard
115 Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.

116 Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet: Marie
117 Warrer Munch*, Marie Helleberg, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno
118 Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan
119 Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard
120 Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.

121 Department of Thoracic Anaesthesiology, Copenhagen University Hospital – Rigshospitalet: Marie
122 Warrer Munch*, Vibeke Lind Jørgensen, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla
123 Meno Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl
124 Johan Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv
125 Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias
126 Saxtorph Aksnes.

127 Department of Neuroanaesthesiology, Copenhagen University Hospital – Rigshospitalet: Marie
128 Warrer Munch*, Margit Smitt, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno
129 Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan
130 Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard
131 Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.

132 Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region,
133 Copenhagen University Hospital – Rigshospitalet: Christian Gluud*, Janus Engstrøm.

134 Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre:
135 Thomas Benfield*, Charlotte Kastberg Levin, Gitte Kronborg, Rikke Krogh-Madsen, Marie Qvist
136 Jensen, Jens Wolfgang Leistner, Camilla Meno Kristensen, Trine Bak Jonassen, Esben
137 Christensen Clapp, Thomas Steen Jensen, Carl Johan Steensen Hjortsø, Matias Metcalf-Clausen,
138 Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen,
139 Emma Victoria Hatley, Tobias Saxtorph Aksnes.

140 Department of Intensive Care, Copenhagen University Hospital – Amager and Hvidovre: Thomas
141 Benfield*, Klaus Tjelle Kristiansen, Ronni Thermann Reitz Plovsing, Marie Qvist Jensen, Jens
142 Wolfgang Leistner, Camilla Meno Kristensen, Trine Bak Jonassen, Esben Christensen Clapp,
143 Thomas Steen Jensen, Carl Johan Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi,
144 Emilie Rose Bak, Liv Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria
145 Hatley, Tobias Saxtorph Aksnes.

146 Department of Respiratory Medicine, Copenhagen University Hospital – Amager and Hvidovre:
147 Thomas Benfield*, Charlotte Suppli Ulrik, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla
148 Meno Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl
149 Johan Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv
150 Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias
151 Saxtorph Aksnes.

152 Department of Anaesthesia and Intensive Care, Herlev Hospital: Anne Sofie Andreasen*, Helene
153 Brix, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno Kristensen, Trine Bak Jonassen,

154 Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan Steensen Hjortsø, Matias Metcalf-
155 Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-
156 Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.

157 Department of Anaesthesia and Intensive Care, Copenhagen University Hospital, North Zealand:
158 Morten H. Bestle*, Martin Schønemann-Lund, Lone Valbjørn, Sanne Lauritzen, Ellen Bjerre Koch,
159 Valdemar Oskar Ingemann Sørensen, Hans Eric Sebastian Seitz-Rasmussen, Frederik Heiberg
160 Bestle.

161 Department of Anaesthesiology, Zealand University Hospital, Køge: Lone Musaeus Poulsen*, Nina
162 Christine Andersen-Ranberg, Camilla Bekker Mortensen, Cecilie Bauer Derby, Kirstine Nanna la
163 Cour, Sarah Weihe, Alison Holten Pind, Emma Ritsmer Stormholt.

164 Department of Anesthesia and Intensive Care, Slagelse Hospital, Slagelse: Anders Møller*, Klaus
165 Vennick Marcussen*, Yifei Cao.

166 Dept. of Anaesthesia and Intensive Care, Odense University Hospital: Thomas Strøm*, Jens
167 Michelsen, Eva Lærkner, Christine Gilberg, Michella Poulsen, Hanne Tanghus Olsen, Charlotte
168 Rosenkilde.

169 Department of Anaesthesia and Intensive Care, Kolding Hospital: Anne Craveiro Brøchner*, Trine
170 Haberlandt.

171 Department of Regional Health Research, Faculty of Health Sciences, University of Southern
172 Denmark: Christian Gluud*.

173 Dept. of Anaesthesiology and Intensive Care, Bispebjerg and Frederiksberg Hospital: Christian
174 Aage Wamberg*, Lars Peter Kloster Andersen, Diana Bertelsen Jensen, Mia Charlotte Krogh
175 Hansen.

176 Department of Anaesthesia, Herning Hospital: Iben Strøm Darfelt*, Nilanjan Dey, Lene Friholdt
177 Mahler.

178 Department of Anaesthesia and Intensive Care, Aalborg University Hospital: Bodil Steen
179 Rasmussen*, Olav Lilleholt Schjørring, Søren Rosborg Aagaard, Stine Rom Vestergaard, Anne-
180 Marie Gellert Bunzel, Rine Moulvad Siegumfeldt, Thomas Lass Klitgaard, Kirsten Uldal Krejberg.

181 Department of Infectious Diseases, Aalborg University Hospital: Bodil Steen Rasmussen*, Henrik
182 Nielsen.

183

184 India

185 Department of Critical Care Medicine, Apollo Main Hospital, Chennai: Bharath Kumar Tirupakuzhi
186 Vijayaraghavan*, Ajay Padmanaban*, Evangeline Elvira, Hilda Nirmala Kumari, Jayanthi
187 Swaminathan, Arun Chander K, Ganesh Rajan N, Sona Thomas, Ann Thomas, Vishnu
188 Odankadummal, Anu M Antony.

189 Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Mumbai: Sheila
190 Nainan Myatra*, Jigeeshu V. Divatia*, Atul P Kulkarni, Nishanth Baliga, Nirmalyo Lodh, Swapna C
191 Vijayakumaran, Tarun Sahu, Kushal Kalvit, Vijaya P Patil, Amol T Kothekar, Shilpushp J Bhosale,
192 Manoj Gorade, Anjana M Shrivastava.

193 Department of Intensive Care. P.D. Hinduja National Hospital & Medical Research Centre: Farhad
194 N. Kapadia*. Jare Jagannath Uddhavrao, Ritika Sharma, Jyotsna Mali, Niranjana H R, Celine Lobo,
195 Vaishali Neve, Deepika Maurya, Mahesh Salunke, Santiswaroop Pattanaik, Akhilesh Agrawal,
196 Ashit Hegde, Rishi Kumar Badgurjar.

197 Department of Critical Care Medicine, Bombay Hospital Institute of Medical Sciences: Pravin R
198 Amin*, Binit N Jhaveri, Digamber B Sarje, Ananda HJ, Bitan Sen, Ambily CM, Emilin P Jose.

199 Intensive Care Unit, S.L. Raheja Fortis Hospital, Mumbai: Sanjith Saseedharan*, Vijayanti
200 Kadam, Annapurna Chiluka, Rohit Kuril, Elizabeth Mathew, Suvarna Shirsekar.

201 Department of Respiratory Medicine, Indraprastha Apollo Hospital, New Delhi: Rajesh Chawla*,
202 Sudha Kansal, Rinku Dahiya, Vijay Kumar Thakur, Rajni Tewatia, Savita Rawat, Harsh Tyagi.

203 Intensive Care Unit, Symbiosis University Hospital and Research Centre, Pune: Urvi Shukla*,
204 Meenakshi Bhakare, Chinmayee Bhise, Amit Girme, Lini T. Kunjumon, Merlin Jose, Nikunj
205 Sharma, Amol Bali.

206 Department of Critical Care Medicine, Sir HN Reliance Foundation Hospital: Mehul Shah*, Mayur
207 Patel, Nirankar Bhutaka, Edwin Pathrose, Gopal Goyal, Riya Baby, Roshini Fernandez.

208 Department of Critical Care Medicine, Rajendra Institute of Medical Sciences: Mohd Saif Khan*,
209 Pradip K Bhattacharya, Srishti Kindo, Aaditya A, Kritika Raj, Aastha Poddar, Aftab Ansari,
210 Mustaque Alam.

211 Department of Internal Medicine, Vishwaraj Hospital, Pune: Kapil Borawake*, Vijay Khandagale,
212 Satish Sarode, Sanesh Garde, Sushant Shinde, Namdev Jagtap, Chagan Khartode, Amit Palange,
213 Aishwarya Pawar, Mayuri Mulay, Simrah Pirzade, Mohini Jagtap, Balbhim Rathod.

214 Department of Anaesthesiology, Gujarat Medical Education & Research Society (GMERS) Medical
215 College and General Hospital, Gotri: Neeta Bose*, Dhara Tanna, Kinjal Chaudhary.

216 Department of Medicine, Gujarat Medical Education & Research Society (GMERS) Medical
217 College and General Hospital, Gotri: Neeta Bose *, Shubhangi Deshpande, Rikin Raj.

218 Department of Critical Care, Sanjeevan Hospital: Subhal Dixit*, Sourab Ambapkar, Shobhana
219 Ambapkar, Mukund Penurkar, Amit Sambare, Ravindra Joshi, Bhushan Kinolkar, Tarannum Aslam
220 Shaikh.

221

222 Sweden

223 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet: Rebecka
224 Rubenson Wahlin*, Maria Cronhjort, Jacob Hollenberg, Anders Hedman, Anton Berggren, Felix
225 Alarcón, Gabriel Yamin, Adam Heymowski.

226 Department of Anaesthesia and Intensive Care, Södersjukhuset: Rebecka Rubenson Wahlin*,
227 Maria Cronhjort, Anton Berggren, Felix Alarcón, Gabriel Yamin, Adam Heymowski.

228 Department of Cardiology, Medical Intensive Care Unit, Södersjukhuset: Rebecka Rubenson
229 Wahlin*, Jacob Hollenberg, Anders Hedman, Anton Berggren, Felix Alarcón, Gabriel Yamin, Adam
230 Heymowski.

231 Department of Anaesthesia and Intensive Care, Universitetssjukhuset i Linköping: Michelle Chew*,
232 Helen Didriksson, Carina Jönsson, Gunilla Gagnö.

233

234 Switzerland

235 Department of Intensive Care Medicine, Bern University Hospital (Inselspital): Luca Cioccarl*,
236 Stephan Jakob, David Zacharias, Margaret Lynn Jong, Marianne Roth, Rachele Mader, Laureta
237 Fazlija, Manuela Akaltan, Anja Eichenberger, Gion Rüegg, Tatjana Dill, Bruno Schoenmaekers.

238 **Acknowledgements**

239 We would like to thank all patients and relatives for agreeing to participate in the COVID STEROID
240 2 trial; all clinical and research staff at the participating hospitals; the regulatory authorities in the
241 participating countries for the expedite handling of the protocol; and the funding sources.

242 We would also like to thank all clinical and research staff involved in the design and conduct of the
243 'Low-dose hydrocortisone in patients with Covid-19 and severe hypoxia (COVID STEROID) trial'
244 which preceded the COVID STEROID 2 trial'.¹

245 .

246

247 **Inclusion Criteria**

- 248 • Adult patients (aged 18 years or above at the time of randomization)
- 249 • Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring
- 250 hospitalisation: we accepted any detections of SARS-CoV-2 approved by the local health
- 251 authorities in the participating countries (i.e. pharyngeal swab, tracheal secretion or
- 252 bronchoalveolar lavage).
- 253 • Use of either of the following:
- 254 - Invasive mechanical ventilation: use of mechanical ventilation via a cuffed endotracheal
- 255 tube **OR**
- 256 - Non-invasive ventilation or continuous use of continuous positive airway pressure
- 257 (CPAP) for hypoxia: Non-invasive ventilation includes positive pressure ventilation via a
- 258 tight mask or helmet, continuous use of CPAP (via mask, helmet or tracheostomy, this
- 259 does not include intermittent use of CPAP) **OR**
- 260 - Oxygen supplementation with an oxygen flow ≥ 10 L/min irrespective of system used
- 261 (mask or nasal cannula) or the addition of atmospheric air.

262 **Exclusion Criteria**

- 263 • Use of systemic corticosteroids for other indications than coronavirus disease 2019 (Covid-
264 19) in doses higher than 6 mg dexamethasone equivalents: systemic corticosteroids (IV,
265 IM, oral or per GI tube; not including nebulized, inhaled or transdermal corticosteroids) in
266 doses higher than 6 mg dexamethasone / 6 mg betamethasone / 200 mg cortisone / 160
267 mg hydrocortisone / 32 mg methylprednisolone / 40 mg prednisolone / 40 mg prednisone.
268 Other indications include adrenal insufficiency (i.e. primary, secondary or tertiary), anti-
269 emetic treatment (i.e. post-operative or chemotherapy-induced nausea and vomiting), and
270 immunosuppressive treatment (i.e. rheumatic diseases, allergic diseases, chronic
271 obstructive pulmonary disease, haematological diseases, chronic kidney diseases,
272 autoimmune hepatitis, inflammatory bowel disease, chronic neurological diseases).
- 273 • Use of systemic corticosteroids for Covid-19 for 5 days or more: use of systemic
274 corticosteroids for Covid-19 for 5 consecutive preceding days or more up to the day of
275 screening.
- 276 • Invasive fungal infection: any of the following:
- 277 - Suspected invasive fungal infection: presence of plasma markers in blood (e.g.
278 candida mannan antigen and galactomannan antigen).
 - 279 - Confirmed invasive fungal infection: positive culture from blood, peritoneal fluid or
280 tissue.
- 281 • Active tuberculosis: either microbiologically confirmed or diagnosed based on
282 epidemiological, clinical and radiographic data.
- 283 • Pregnancy: confirmed by positive urine human gonadotropin (hCG) or plasma-hCG. A
284 negative urine or plasma-HCG test was mandatory for all women below 60 years of age.
- 285 • Known hypersensitivity to dexamethasone: history of any hypersensitivity reaction to
286 dexamethasone, including but not limited to urticaria, eczema, angioedema, bronchospasm
287 and anaphylaxis.
- 288 • Previously randomized in the COVID STEROID 2 trial: patients who had previously been
289 randomized in the COVID STEROID 2 trial, either during current or former hospitalisation.
- 290 • Informed consent not obtainable: patients where the clinician or investigator was unable to
291 obtain the necessary consent according to the national regulations, including patients with
292 no relatives or patients who were hospitalized against their will.

293 **Baseline Characteristics**

- 294 • Sex: the genotypic sex of the participant.
- 295 • Age at enrolment: the age of the participant in whole years at the time of randomization.
- 296 The age will be calculated from the date of birth and date of enrolment in the COVID
- 297 STEROID 2 trial.
- 298 • Date of admission to hospital: the date of admission to the first hospital the participant was
- 299 admitted to during the current hospital admission.
- 300 • Number of days with symptoms of COVID-19 before hospital admission: the total number of
- 301 days (as integer) with symptoms of COVID-19 before hospital admission. If the symptoms
- 302 started on the same day as hospital admission, the number of days with symptoms before
- 303 hospital admission will be registered as 1. If the patient was infected while in hospital, the
- 304 number of days with symptoms before hospital admission will be registered as 0.
- 305 • Department at which participant was included:
- 306 - Emergency department: accident/emergency/casualty/acute department at COVID
- 307 STEROID 2 trial sites.
- 308 - Hospital ward: medical or surgical ward at COVID STEROID 2 trial site, including
- 309 dedicated COVID-19 hospital wards.
- 310 - Intermediate care unit: area of the hospital with higher resources to monitor patients
- 311 as defined by the site, but invasive mechanical cannot be given.
- 312 - Intensive care unit: area of the hospital where invasive mechanical can be given.
- 313 Other: any location in the same or another hospital not covered in the other
- 314 categories.
- 315 • Use of respiratory support at randomization:
- 316 - Closed system (y/n): Use of invasive mechanical ventilation or non-invasive
- 317 ventilation or continuous use of continuous positive airway pressure (CPAP) for
- 318 hypoxia (defined in Supporting Information S2). If yes, latest FiO₂ prior to
- 319 randomization.
- 320 - Open system with an oxygen flow ≥ 10 L/min: defined in Supporting Information S2.
- 321 If yes, the maximum supplemental oxygen flow on an open system at randomization
- 322 (+/- 1 h) will be registered.
- 323 • Limitations of care (y/n): participant with limitation(s) in use of life support (i.e. invasive
- 324 mechanical ventilation, circulatory support, renal replacement therapy) and/or cardio-
- 325 pulmonary resuscitation at the time of randomization.

- 326
- 327
- 328
- 329
- 330
- 331
- 332
- 333
- 334
- 335
- 336
- 337
- 338
- 339
- 340
- 341
- 342
- 343
- 344
- 345
- 346
- 347
- 348
- 349
- 350
- 351
- 352
- 353
- 354
- 355
- 356
- 357
- 358
- 359
- Chronic use of systemic corticosteroids for other indications than COVID-19 (y/n): systemic corticosteroids (IV, IM, oral or per GI tube; not including nebulized, inhaled or transdermal corticosteroids) for any other indications than COVID-19 at the time of randomization.
 - Treatment during current hospital admission prior to randomization:
 - Agents with potential anti-viral action used against COVID-19: any treatment that potentially inhibits viral replication, categorised as remdesivir, convalescent plasma, or other (e.g. umifenovir, interferon alfa, interferon beta, camostat).
 - Anti-bacterial agents: any antibiotic treatment commenced due to documented or suspected bacterial infection before microbiological results are available.
 - Agents with potential anti-inflammatory action: any treatment with potential anti-inflammatory actions used against COVID-19 prior to screening, categorised as Janus kinase inhibitor, IL-6 inhibitors or other.
 - Co-morbidities: any chronic co-morbidity present in the past medical history prior to admission and defined as follows:
 - History of ischemic heart disease or heart failure: previous myocardial infarction, invasive intervention for coronary artery disease, stable or unstable angina, NYHA class 3 or 4 or any measured left ventricular ejection fraction (LVEF) <40%.
 - Diabetes mellitus: treatment at time of hospital admission with any anti-diabetic medications.
 - Chronic pulmonary disease: treatment at time of hospital admission with any relevant drug indicating chronic pulmonary disease.
 - Immunosuppressive therapy within the last 3-months: use of systemic immunosuppressive drugs (e.g. tumor necrosis factor (TNF) inhibitors, calcineurin inhibitors, mTOR inhibitors, anti-thymocyte globulins, interleukin-2 inhibitors, mycophenolate, azathioprine, belimumab, corticosteroids), chemotherapy (e.g. alkylating agents, anti-metabolites, mitotic inhibitors, topoisomerase inhibitors, others) or radiotherapy within the last 3 months before randomization.
 - Blood values, interventions and vital parameters:
 - Participant weight: measured or estimated in kilograms.
 - PaO₂, SaO₂ and lactate prior to inclusion: will be assessed from the most recent arterial blood gas sample; alternatively, if arterial blood gas sample is not available, SpO₂ will be assessed from the most recent measure by pulse oximeter.
 - Circulatory support: infusion of any vasopressor/inotrope agent for a minimum of 1 hour (i.e. norepinephrine, epinephrine, phenylephrine, vasopressin analogues,

360 angiotensin, dopamine, dobutamine, milrinone or levosimendan) within the last 24
361 hours prior to randomization.
362 - Renal replacement therapy: any form of acute or chronic intermittent or continuous
363 renal replacement therapy (including days between intermittent dialysis) within the
364 last 72 hours prior to randomization.
365

366 **Outcome definitions**

367

368 **Primary outcome**

369 The days alive without life support at day 28 was calculated as the total number of days alive
370 without any of the 3 life supporting interventions (listed below) within 28 days after randomization.

371 Use of life support was defined as the need for:

- 372
- 373 • Invasive mechanical ventilation: use of mechanical ventilation via a cuffed endotracheal
374 tube.
 - 375 • Circulatory support: infusion of any vasopressor/inotrope agent for a minimum of 1 hour (i.e.
376 norepinephrine, epinephrine, phenylephrine, vasopressin analogues, angiotensin,
377 dopamine, dobutamine, milrinone or levosimendan).
 - 378 • Renal replacement therapy: any form of acute or chronic intermittent or continuous renal
379 replacement therapy (RRT), including days between intermittent RRT. We defined periods
380 with up to 3 days between intermittent RRT as days with RRT (e.g. if a patient received
381 RRT on day 1, did not receive RRT on days 2-4, and received RRT again on day 5, the
382 patient was considered on RRT on days 1-5).

383 **Secondary outcome**

384 1. Number of patients with one or more serious adverse reactions (SARs) at day 28 was
385 assessed as at least one of the following on each day from randomization to day 28:

- 386
- 387 • New episodes of septic shock: we defined septic shock according to the Sepsis-3
388 criteria:²
 - 389 - Suspected or confirmed superinfection.
 - 390 - New infusion (or 50% increase) of vasopressor/inotropic agent (i.e.
391 norepinephrine, epinephrine, phenylephrine, vasopressin analogues,
392 angiotensin, dopamine, dobutamine, milrinone or levosimendan) to maintain a
393 mean arterial blood pressure of 65 mmHg or above.
 - 394 - Lactate of 2 mmol/L or above in any plasma sample performed on the same day
 - 394 • Invasive fungal infection: any of the following:

- 395 - Suspected invasive fungal infection: presence of plasma markers in blood (e.g.
396 candida mannan antigen and galactomannan antigen).
- 397 - Confirmed invasive fungal infection: positive culture from blood, peritoneal fluid
398 or tissue.
- 399 • Clinically important gastrointestinal (GI) bleeding was assessed as any GI bleeding
400 **AND** the use of at least 2 units of red blood cells on the same day. GI bleeding defined
401 as hematemesis, coffee ground emesis, melena, haematochezia or bloody nasogastric
402 aspirate on this day.
- 403 • Anaphylactic reaction to IV dexamethasone: anaphylactic reactions was only recorded
404 during the intervention period (i.e. for up to 10 days depending on the number of days
405 with corticosteroid use before randomization). An anaphylactic reactions was defined as
406 urticarial skin reaction **AND** at least one of the following observed after randomization
- 407 - Worsened circulation (>20% decrease in blood pressure or >20% increase in
408 vasopressor dose).
- 409 - Increased airway resistance (>20% increase in the peak pressure on the
410 ventilation)
- 411 - Clinical stridor or bronchospasm.
- 412 - Subsequent treatment with bronchodilators.
- 413 2. All-cause mortality at day 28 after randomization: death from any cause within 28 days
414 post-randomization.
- 415

416 The following secondary longer-term outcomes are also registered in the COVID STEROID 2 trial³
417 but will be reported later when follow-up has completed.

- 418 1. All-cause mortality at day 90 after randomization.
- 419 2. Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or
420 renal replacement therapy) at day 90.
- 421 3. Days alive and out of hospital at day 90.
- 422 4. All-cause mortality at 180 days after randomization.
- 423 5. Health-Related Quality of Life (HRQoL) at 180 days after randomization assessed by EQ-
424 5D-5L.

425 6. Health-Related Quality of Life (HRQoL) at 180 days after randomization assessed by EQ-
426 VAS.

427 **Criteria for Discontinuation of Trial Medication and Withdrawal**
428

429 The procedure for handling withdrawal of consent from a patient followed national regulations.
430

431 **Discontinuation and withdrawal at the choice of the patient or the proxy**

432 The patient or next of kin could withdraw his/her consent or proxy consent at any time without
433 further explanations and without consequences for further treatment. In these instances, the
434 investigator asked the patient or next of kin if they allowed continued data registration and follow-
435 up until day 180. Already collected data up until the time of withdrawal were used according to
436 national regulations.

437 If the patient was withdrawn before the first dose of trial medication was administered, the patient
438 was not considered a part of the intention-to-treat (ITT) population. If the patient was withdrawn
439 after one or more doses of trial medication were administered, and the patient or next of kin
440 allowed continued data registration, the patient remained in the ITT population. If the patient was
441 withdrawn after one or more doses of trial medication were administered, and the patient or next of
442 kin did not allow continued data registration, the patient remained in the ITT population but with
443 missing data from the time of withdrawal. For patients withdrawn in Switzerland due to withdrawal
444 of consent, all registered data were deleted, including the data registered before the time of
445 withdrawal as required by the Swiss Ethics Committee. Any such Swiss patient was not part of the
446 ITT population.

447
448

449 **Discontinuation and withdrawal at the choice of the investigator**

450 A patient could have the intervention stopped by the clinician or investigator at any time if:

- 451 • The patient experienced intolerable adverse reactions or events (including SARs or suspected
452 unexpected serious adverse reactions (SUSARs)) suspected to be related to the trial
453 intervention.
- 454 • The clinicians in conjunction with the coordinating investigator decided it to be in the interest of
455 the patient.
- 456 • The patient was withdrawn from active therapy.
- 457 • The patient was subject to compulsory hospitalisation.

458

459 In these patients, the collection of data and the follow-up continued, and the patient remained in
460 the ITT population.

461 **Trial Populations**

462

463 **Definition of the ITT population**

464 The ITT population was defined as all randomized patients and for whom there was consent for the
465 use of data.

466

467 **Definition of the per-protocol population**

468 The per-protocol population was defined as the ITT population except those having one or more
469 major protocol violations during the intervention period (for up to 10 days depending on the number
470 of consecutive days with corticosteroid use before randomization) defined as:

- 471
- 472 • Use of open-label systemic corticosteroids.
 - 473 • Trial medication not administered as per protocol (1 bolus injection of either 12 mg or 6 mg
474 dexamethasone according to the allocation on each day during the intervention period).

474 Patients who discontinued trial medication due to withdrawal of consent or for clinical reasons were
475 considered as part of the per-protocol population.

476 **Handling of Missing Data**

477

478 **Complete missingness of data**

479 We had complete missingness of data for 5 patients who withdrew consent and had all registered
480 data deleted, including the data registered before the time of withdrawal as required by the Swiss
481 Ethics Committee.

482

483 **Missing baseline variables**

484 We had missing source data for the time from onset of symptoms to hospital admission for 32
485 patients allocated to dexamethasone 12 mg and for 18 patients allocated to dexamethasone 6 mg;
486 for the fraction of inspired oxygen for patients receiving invasive mechanical ventilation for 1
487 patient allocated to dexamethasone 12 mg; for the fraction of inspired oxygen for patients receiving
488 non-invasive ventilation or continuous use of CPAP for 4 patients allocated to dexamethasone 12
489 mg and for 8 patients allocated to dexamethasone 6 mg; for the most recent partial pressure of
490 oxygen (PaO₂) prior to randomization for 28 patients allocated to dexamethasone 12 mg and for
491 23 patients allocated to dexamethasone 6 mg; for the most recent arterial oxygen saturation prior
492 to randomization for 5 patients allocated to dexamethasone 12 mg and for 9 patients allocated to
493 dexamethasone 6 mg; and for the highest plasma lactate value in the last 24 hours prior to
494 randomization for 57 patients allocated to dexamethasone 12 mg and for 49 patients allocated to
495 dexamethasone 6 mg. The missing data in these patients were not included in the baseline
496 characteristics.

497

498 **Missing outcome data**

499 Primary outcome

500 We had data for the primary outcome for 971 of 982 (98.9%) patients in the ITT population (98.8%
501 in patients allocated to dexamethasone 12 mg; 99.0% in patients allocated to dexamethasone 6
502 mg). 11 patients had missing data due to withdrawal of consent from the time of withdrawal; no
503 patients were lost to follow-up.

504

505

506

507 Secondary outcomes

508 We had data for 28-day mortality for 971 of 982 (98.9%) patients in the ITT population (98.8% in
509 patients allocated to dexamethasone 12 mg; 99.0% in patients allocated to dexamethasone 6 mg).
510 11 patients had missing data due to withdrawal of consent from the time of withdrawal; no patients
511 were lost to follow-up.

512 We analyzed data for SARs for all 982 patients in the ITT population. For the 11 patients who
513 withdrew consent before 28-days follow up, the occurrence of serious adverse reactions was
514 analyzed until the day of withdrawal of consent

515

516 **Logical imputation**

517 We used logical imputation for one patient that likely left the country of enrolment before 28-days
518 follow-up. The patient was last seen alive 3 days before 28-days follow up, where the patient was
519 assessed to be fit-to-fly by a medical doctor. Consequently, the patient was assumed to be alive,
520 without the need for life support, and without any serious adverse reactions after discharge and
521 until day 28 after randomization.

522 We used logical imputation for one patient for whom the relatives could inform that the patient had
523 received renal replacement therapy after discharge, but not the number of days with renal
524 replacement therapy after discharge. The patient died on day 46 after randomization. For this
525 patient, we assumed that the patient received renal replacement therapy (including days in
526 between intermittent renal replacement therapy) at all days from discharge to 28-days follow-up.

527

528

529

530 **Abstract Written before Breaking the Randomization Code**
531 **v. 1.3, June 26, 2021, approved by the Management Committee**

532 **Background**

533 Dexamethasone 6 mg daily is recommended for up to 10 days in patients with severe and critical
534 Covid-19. A higher dose of dexamethasone may benefit those with more severe disease.

535

536 **Methods**

537 In this international, blinded trial, we randomly assigned adults with confirmed Covid-19 receiving
538 at least 10 L/min of oxygen or mechanical ventilation to intravenous dexamethasone 12 mg or
539 dexamethasone 6 mg daily for up to 10 days. The primary outcome was the number of days alive
540 without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement
541 therapy) at 28 days.

542

543 **Results**

544 We randomized 1000 patients, included 982 in the intention-to-treat-population and had primary
545 outcome data for 971, among whom 491 patients were assigned to dexamethasone A mg and 480
546 patients assigned to dexamethasone B mg. The median number of days alive without life support
547 at 28 days was 22.0 days (interquartile range 6.0-28.0) in the A mg group and 20.5 days (4.0-28.0)
548 in the B mg group (adjusted mean difference 1.3 days, 95% confidence interval (CI), 0.0-2.6;
549 P=0.066). The 28-day mortality was 27.1% and 32.3% in patients assigned to A mg and B mg,
550 respectively, (adjusted relative risk 0.86, 99% CI, 0.68-1.09). The 28-day occurrence of serious
551 adverse reactions were similar in the two groups (adjusted relative risk 0.85, 99% CI, 0.56-1.31).

552

553 **Conclusions**

554 Among patients with Covid-19 and severe hypoxia, dexamethasone A mg probably led to more
555 days alive without life support at 28 days than dexamethasone B mg.

556

557 **Note, 28 June 2021.** The upper confidence interval for 28-day mortality differs between the abstract written before
558 breaking the randomization code and the final one due to simulation uncertainty and rounding; these estimates were
559 calculated using logistic regression and g-computation, which involved a bootstrap resampling procedure to estimate
560 confidence intervals, with 5,000 samples used in the analyses conducted before unblinding and 50,000 samples used in
561 the final analyses.

562 **Note, 21 July 2021.** Four serious adverse reactions were refuted when reviewed before final reporting to institutional
563 ethics committees. The adjusted relative risk therefore differs between the abstract written before breaking the
564 randomization code and the final one.


565 **eFigures**

566

567 **eFigure 1. Masking of Trial Medication**

568 We used shelf-medications from the hospital department's pharmacy for the trial interventions. To
569 ensure blinding, the trial medications were prepared by a team of unblinded trial staff; all others,
570 including the patients and clinical staff, remained blinded to the treatment allocation. For each
571 patient, the trial medication was be prepared once daily and administered as a bolus injection
572 intravenously.

573 Dexamethasone phosphate (used at all hospitals except in the one Swedish hospital where
574 bethamethasone phosphate was used) is a clear colourless solution. To ensure blinding, the
575 dexamethasone phosphate solution was mixed with isotonic saline (0.9%) to a bolus volume of 5
576 ml for both trial interventions. Consequently, the 12 mg and 6 mg dexamethasone bolus injections
577 appeared identical upon visual inspection (eFigure 1). The preparation of trial medication is
578 described in detail in the Supporting Information S5 in the primary protocol.³



<p style="text-align: center;">COVID STEROID 2 trial medication for clinical trial Dexamethasone 12 mg OR dexamethasone 6 mg</p> <p>For injection</p> <p>Patient name.....</p> <p>Identification number.....</p> <p>Date and time of preparation of trial medication.....</p> <p>Signature.....</p> <p>Must be stored at $\leq 25^{\circ}\text{C}$</p> <p>Questions? Contact HOTLINE tel. +45 3545 7237</p> <p>Sponsor: Prof. Anders Perner, Dept. of Intensive Care, Rigshospitalet, Denmark. Tel. +45 3545 8333</p>

579

580 **eFigure 1. Masking of trial medication.** Trial interventions (12 mg and 6 mg of dexamethasone)
581 without labels (to the left). Both interventions were labelled with identical labels (to the right).

582

583

584

585 **Local trade names**

586 The local trade names used in the COVID STEROID 2 trial are listed below.

587

588 Denmark

589 Dexavit™, Vital Pharma Nordic, Denmark, ATC code: H02AB02.

590

591 Sweden

592 Betapred™, Alfasigma S.p.A., Italy, ATC code: H02AB01.

593 Dexavit™, Vital Pharma Nordic, Denmark, ATC code: H02AB02.

594

595 Switzerland

596 Mephameson™, Mepha Pharma AG, Switzerland, ATC code: H02AB02.

597

598 India

599 Dakson™, Daksh Pharmaceuticals Pvt. Ltd, India, ATC code: H02AB02.

600 Dacdac™, Wockhardt Limited (Merind), India, ATC code: H02AB02.

601 Decmax™, GLS Pharma Ltd., India, ATC code: H02AB02.

602 Demisone™, Cadila Pharmaceuticals Ltd. (Genvista), India, ATC code: H02AB02.

603 Dexona™, Zydus Cadila Healthcare Ltd. (Alidac), India, ATC code: H02AB02.

604 Dex-V™, Vensat Bio, India, ATC code: H02AB02.

605 Intradex™, Intra Labs India Pvt. Ltd, India, ATC code: H02AB02.

606 eFigure 2. Number of Enrolments per Site

607



608


609 The 4 sites at Rigshospitalet, Denmark, was run by one research staff team; so was the 3 sites at Hvidovre Hospital, Denmark.

610

611

612

613 **eFigure 3. Number of Enrolments per Month**
614




615
616
617
618
619
620
621

622

623 **eFigure 4. Distributions of the Primary Outcome in the Post Hoc Analyses of the Primary Outcome Assigning Patients**
624 **Who had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)**

625



626

627 eFigure 4 shows the number of days alive without life support as horizontally stacked proportions in the two intervention groups in the
628 intention-to-treat population in the *post hoc* analysis assigning patients who had died at day 28 the worst possible outcome of 0 days alive
629 without life support at day 28 after randomization (n=971; 11 patients had missing primary outcome data). Red represents worse
630 outcomes, and blue represents better outcomes.

631 **eTables**

632

633 **eTable 1a and 1b. Randomizations in Error and Wrongly Entered Stratification**
 634 **Variables**

635

636 **eTable 1a: Randomizations in error**

Reason for randomization in error	Number of patients
Ineligible at the time of randomization ^a	8
Did not fulfill inclusion criteria ^b	4
Fulfilled one or more exclusion criteria ^c	4
Duplicate randomizations ^d	1

^a All 8 patients were included in the ITT population.

^b 3 patients received less than 10 L/min of supplementary oxygen and 1 was PCR-negative for SARS-CoV-2.

^c 3 had received corticosteroids for Covid-19 for 5 consecutive days or more, and 1 had an indication for systemic corticosteroids in a dose higher than dexamethasone 6 mg or equivalent.

^d The patient received trial medication according to the allocation at the first randomization and was only included once in the ITT population.

637

638 **eTable 1b: Wrongly entered stratification variables**

Stratification variable^a	Number of patients
Site ^b	6
Invasive mechanical ventilation	7
Age below 70 years	18

^a The wrongly entered stratification variables were corrected for all these 31 patients before the adjusted analyses were conducted.

^b Some investigators had access to more than one site in the electronic case report form where screening was performed. As a result, 6 patients were administratively allocated at a wrong site.

639 **eTable 2. Trial Medication Administration and Protocol Violations**
 640

	Dexamethasone 12 mg (n=497)	Dexamethasone 6 mg (n=485)
Trial medication administration		
Treatment duration, median (IQR), days	7 (5 - 9)	7 (6 - 9)
Major protocol violation, no. (%)	44 (8.9%)	46 (9.5%)
Use of open-label systemic corticosteroids	10 (2.0%)	9 (1.9%)
Trial medication not administered as per protocol	36 (7.2%)	39 (8.0%)

641 Abbreviations: mg, milligrams; IQR, interquartile range.

642 **eTable 3. Results of the Analysis of the Primary Outcome in the Per Protocol**
 643 **Population^a**
 644

Primary outcome	Dexamethasone 12 mg (N=453)	Dexamethasone 6 mg (N=439)	Mean difference (95% CI)^b	Median difference (95% CI)^b
Number of days alive without life support, median (IQR) ^c	23.0 (6.0-28.0)	20.0 (4.0-28.0)	1.3 (0.0 to 2.7)	0 (-0.9 to 0.9)

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

^a Defined as the ITT population except those having one or more major protocol violations (i.e. use of open-label systemic corticosteroids and/or trial medication not administered as per protocol) during the intervention period (N = 892).

^b Significance level is set to 5% including the interim analysis. Accordingly, we have employed 95.08% confidence intervals for the final analysis.

^c Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years).

645
646

eTable 4. Best-Worst/Worst-Best Case Analyses of the Primary Outcome

	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)	Mean difference (95% CI)^a	Median difference (95% CI)^a
Best-worst case analysis^b				
Number of days alive without life support, median (IQR)	22.0 (6.0-28.0)	20.0 (4.0-28.0)	1.6 (0.3 to 2.9)	0 (-0.8 to 0.8)
Worst-best case analysis^c				
Number of days alive without life support, median (IQR)	22.0 (5.0-28.0)	21.0 (4.0-28.0)	1.1 (-0.2 to 2.4)	0 (-0.5 to 0.5)

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

^a Significance level is set to 5% including the interim analysis. Accordingly, we have employed 95.08% confidence intervals for the final analysis. Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years).

^b Analyzed assuming all patients lost to follow-up in the 12 mg group have had a beneficial outcome (i.e. assuming that the patient was alive and without life support for all days with missing data) and all patients lost to follow-up in the 6 mg group have had a harmful outcome (i.e. assuming that the patient was dead and/or received life support on all days with missing data).

^c Analyzed assuming all patients lost to follow-up in the 12 mg group have had a harmful outcome (i.e. assuming that the patient was dead and/or received life support on all days with missing data) and all patients lost to follow-up in the 6 mg group have had a beneficial outcome (i.e. assuming that the patient was alive and without life support for all days with missing data).

647
648
649

eTable 5. Post Hoc Analyses of the Primary Outcome Assigning Patients Who Had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)

Outcome	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)	Mean difference (95% CI) ^a	Median difference (95% CI) ^a
Primary outcome^b				
Number of days alive without life support, median (IQR)	22 (0 - 28)	20 (0 - 28)	1.5 (0.1 to 3.0)	0 (-1.1 to 1.1)
Number of days alive without invasive mechanical ventilation, median (IQR)	23 (0 - 28)	21 (0 - 28)		
Number of days alive without circulatory support, median (IQR)	26 (0 - 28)	25 (0 - 28)		
Number of days alive without renal replacement therapy, median (IQR) ^c	28 (0 - 28)	28 (0 - 28)		

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

Before the lock of the trial database, we decided to do this *post hoc* sensitivity analysis assigning dead patients the worst possible outcome (i.e. 0 days alive without life support) as this as previously been proposed and is frequently used in other, similar trials.^{4,5}

^a Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years. Significance level is set to 5% including the interim analysis for the primary outcome. Accordingly, we have employed 95.08% confidence interval for the primary outcome.

^b Defined as days alive and without the use of invasive mechanical ventilation, circulatory support or renal replacement therapy. Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg.

^c Any form of acute or chronic intermittent or continuous renal replacement therapy, including days between intermittent dialysis (i.e. we have considered up to 3 days in between renal replacement therapy as days with renal placement therapy).

eTable 6. Analyses of the Single Components of Composite Outcomes

Outcomes at day 28	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)	Mean difference (95% CI) ^a	Median difference (95% CI) ^a
Primary outcome: days alive without life support^b				
Number of days alive without invasive mechanical ventilation, median (IQR)	23 (7 - 28)	22 (5 - 28)	1.0 (-0.3 to 2.2)	0 (-0.5 to 0.5)
Number of days alive without circulatory support, median (IQR)	26 (13 - 28)	25 (9 - 28)	1.0 (-0.2 to 2.2)	0 (-0.1 to 0.1)
Number of days alive without renal replacement therapy, median (IQR) ^c	28 (18 - 28)	28 (14 - 28)	0.7 (-0.4 to 1.8)	- ^d
Secondary outcome: serious adverse reactions, no. (%)^e			Relative risk (99% CI)^a	Risk difference (99% CI)^a
New episodes of septic shock	42 (8.5%)	49 (10.1%)	0.85 (0.50 to 1.43)	-1.5 (-6.2 to 3.2)
Invasive fungal infection	15 (3.0%)	21 (4.3%)	0.70 (0.27 to 1.64)	-1.3 (-4.2 to 1.7)
Clinically important gastrointestinal bleeding	9 (1.8%)	5 (1.0%)	- ^f	- ^f
Anaphylactic reaction to intravenous dexamethasone ^g	0 (0.0%)	0 (0.0%)	-	-

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

^a Significance level is set to 5% including the interim analysis. Accordingly, we have employed 95.08% confidence interval for the primary outcome, and 99% confidence intervals for the secondary outcomes. Risk differences are reported in percentage points.

^b Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years). Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg.

^c Any form of acute or chronic intermittent or continuous renal replacement therapy, including days between intermittent dialysis (i.e. we have considered up to 3 days in between renal replacement therapy as days with renal placement therapy).

^d Not applicable as too many observations are identical.

^e Analyzed using logistic regression and g-computation adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years).

^f Too few events to be meaningfully analyzed.

^g Only recorded during the intervention period (for up to 10 days).

652
653

eTable 7. Results of the Unadjusted Analyses of Secondary Outcomes

Secondary outcomes^a	Relative risk (99% CI)	Risk difference (99% CI)
Death by day 28	0.84 (0.65 to 1.08)	-5.2 (-12.7 to 2.3)
Patients with one or more serious adverse reactions ^b	0.85 (0.61 to 1.19)	-1.9 (-6.1 to 2.2)

Abbreviations: CI, confidence interval.

^a Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg. Both outcomes are analyzed using generalized linear models with log/identity links and binomial error distributions. Risk differences are reported in percentage points.

^b Defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding or anaphylactic reaction to intravenous dexamethasone.

654
655

eTable 8. All Serious Adverse Reactions and Serious Adverse Events^a

	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)
SARs registered in addition to those in the SAR-outcome, no. (%)^b		
Sepsis	2 (0.4%)	5 (1.0%)
Bacteraemia	4 (0.8%)	1 (0.2%)
Pneumonia	6 (1.2%)	7 (1.4%)
<i>C. difficile</i>	0 (0.0%)	1 (0.2%)
Other	3 (0.6%)	3 (0.6%)
Total ^c	14 (2.8%)	17 (3.5%)
SAEs, no. (%)^d		
Thromboembolic events	4 (0.8%)	10 (2.1%)
Bleeding	7 (1.4%)	7 (1.4%)
Acute kidney injury	52 (10.5%)	62 (12.8%)
Pulmonary complications, including pneumothorax	3 (0.6%)	3 (0.6%)
Circulatory failure, including cardiac arrest	9 (1.8%)	9 (1.9%)
Other	7 (1.4%)	3 (0.6%)
Total ^e	70 (14.1%)	85 (17.5%)
Patients with one or more SARs or SAEs, no. (%)^f	108 (21.7%)	130 (26.8%)

Abbreviations: mg, milligrams; SAE, serious adverse event; SAR, serious adverse reaction.

^a SAE and any SAR (both those included in the SAR-outcome (i.e. new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding, or anaphylactic reaction to intravenous dexamethasone) and those reported directly to Sponsor or his delegate by e-mail or using a standardized report form).

^b Other registered SARs, i.e. adverse reactions registered in the Summary Product Characteristic for dexamethasone considered serious and not registered in the secondary SAR outcome.

^c Total number of patients with at least one SAR not included in the secondary SAR outcome.

^d Any SAE not considered a SAR.

^e Total number of patients with at least one SAE.

^f Including the reactions reported in the secondary SAR outcome.

656

657

658 **eTable 9. Use of Extracorporeal Membrane Oxygenation within 28 Days of**
659 **Randomization^a**
660

	Dexamethasone 12 mg	Dexamethasone 6 mg
Extracorporeal membrane oxygenation, no. (%)	3 (0.6%)	14 (2.9%)

Abbreviations: mg, milligrams.

^a Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg.

661
662

eTable 10. Discharge Against Medical Advice within 28 Days of Randomization

	Dexamethasone 12 mg	Dexamethasone 6 mg
Discharged against medical advice, no. (%)	9 (1.8%)	11 (2.3%)
Use of life support at the time of discharge	1 (0.2%)	1 (0.2%)
Invasive mechanical ventilation	1 (0.2%)	1 (0.2%)
Circulatory support	0 (0.0 %)	0 (0.0 %)
Renal replacement therapy ^a	0 (0.0 %)	0 (0.0 %)
Use of supplementary oxygen at the time of discharge	5 (1.0%)	8 (1.7%)
≥ 10 l/min	2 (0.4%)	3 (0.6%)
0-9 l/min	3 (0.6%)	5 (1.0%)

Abbreviations: mg, milligrams; l, liters; min, minutes.

^a Any form of acute or chronic intermittent or continuous renal replacement therapy, including days between intermittent dialysis (i.e. we have considered up to 3 days in between renal replacement therapy as days with renal placement therapy).

663 **eReferences**

- 664 1. Munch MW, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with
665 COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial.
666 *Acta Anaesthesiol Scand.* 2021.
- 667 2. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
668 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA.* 2016;315(8):801-810.
- 669 3. Munch MW, Granholm A, Myatra SN, et al. Higher vs lower doses of dexamethasone in
670 patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and
671 statistical analysis plan. *Acta Anaesthesiol Scand.* 2021;65(6):834-845.
- 672 4. Schoenfeld DA, Bernard GR, Network A. Statistical evaluation of ventilator-free days as an
673 efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. *Crit*
674 *Care Med.* 2002;30(8):1772-1777.
- 675 5. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ
676 Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid
677 Domain Randomized Clinical Trial. *JAMA.* 2020;324(13):1317-1329.

678